These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 2984982)
1. Duration of effect of interferon aerosol prophylaxis of vesicular stomatitis virus infection in mice. Wyde PR; Sun CS; Wilson SZ; Knight V Antimicrob Agents Chemother; 1985 Jan; 27(1):60-4. PubMed ID: 2984982 [TBL] [Abstract][Full Text] [Related]
2. Interferon aerosol suppression of vesicular stomatitis virus replication in the lungs of infected mice. Wyde PR; Wilson SZ; Sun CS; Knight V Antimicrob Agents Chemother; 1984 Oct; 26(4):450-4. PubMed ID: 6097164 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of aerosolized recombinant interferons against vesicular stomatitis virus-induced lung infection in cotton rats. Sun CS; Wyde PR; Wilson SZ; Knight V J Interferon Res; 1984; 4(4):449-59. PubMed ID: 6094681 [TBL] [Abstract][Full Text] [Related]
4. Pulmonary deposition and clearance of aerosolized interferon. Wyde PR; Wilson SZ; Kramer MJ; Sun CS; Knight V Antimicrob Agents Chemother; 1984 Jun; 25(6):729-34. PubMed ID: 6742817 [TBL] [Abstract][Full Text] [Related]
5. Limited efficacy of aerosolized recombinant alpha interferon against virulent influenza A/HK infection in mice. Sun CS; Wilson SZ; Wyde PR Proc Soc Exp Biol Med; 1986 Feb; 181(2):298-304. PubMed ID: 3945639 [TBL] [Abstract][Full Text] [Related]
6. Interferon in experimental viral infections in mice: tissue interferon levels resulting from the virus infection and from exogenous interferon therapy. Heremans H; Billiau A; De Somer P Infect Immun; 1980 Nov; 30(2):513-22. PubMed ID: 6160109 [TBL] [Abstract][Full Text] [Related]
7. Requirements for DI particle prophylaxis against vesicular stomatitis virus infection in vivo. Jones CL; Holland JJ J Gen Virol; 1980 Jul; 49(1):215-20. PubMed ID: 6252288 [TBL] [Abstract][Full Text] [Related]
8. Prevention of viral myocarditis with recombinant human leukocyte interferon alpha A/D in a murine model. Matsumori A; Crumpacker CS; Abelmann WH J Am Coll Cardiol; 1987 Jun; 9(6):1320-5. PubMed ID: 3034992 [TBL] [Abstract][Full Text] [Related]
9. Antiviral activities of cloned human leukocyte interferons against herpes simplex virus type 2 infections of mice. Fish EN; Banerjee K; Stebbing N J Gen Virol; 1983 Oct; 64 (Pt 10)():2317-21. PubMed ID: 6684674 [TBL] [Abstract][Full Text] [Related]
10. Mediators of protection against lethal systemic vesicular stomatitis virus infection in hamsters: defective interfering particles, polyinosinate-polycytidylate, and interferon. Fultz PN; Shadduck JA; Kang CY; Streilein JW Infect Immun; 1982 Aug; 37(2):679-86. PubMed ID: 6180986 [TBL] [Abstract][Full Text] [Related]
11. Intranasal interferon-alpha 2 prophylaxis of natural respiratory virus infection. Douglas RM; Albrecht JK; Miles HB; Moore BW; Read R; Worswick DA; Woodward AJ J Infect Dis; 1985 Apr; 151(4):731-6. PubMed ID: 2982972 [No Abstract] [Full Text] [Related]
12. A study of intranasally administered interferon A (rIFN-alpha 2A) for the seasonal prophylaxis of natural viral infections of the upper respiratory tract in healthy volunteers. Tannock GA; Gillett SM; Gillett RS; Barry RD; Hensley MJ; Herd R; Reid AL; Saunders NA Epidemiol Infect; 1988 Dec; 101(3):611-21. PubMed ID: 3215290 [TBL] [Abstract][Full Text] [Related]
14. The role of interferon in the protective effect of a synthetic double-stranded polyribonucleotide against intranasal vesicular stomatitis virus challenge in mice. De Clercq E; Nuwer MR; Merigan TC J Clin Invest; 1970 Aug; 49(8):1565-77. PubMed ID: 4317283 [TBL] [Abstract][Full Text] [Related]
15. Antiviral and protein-inducing activities of recombinant human leukocyte interferons and their hybrids. Sen GC; Herz R; Davatelis V; Pestka S J Virol; 1984 May; 50(2):445-50. PubMed ID: 6200607 [TBL] [Abstract][Full Text] [Related]
16. Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses. Gresser I; Tovey MG; Maury C; Bandu MT J Exp Med; 1976 Nov; 144(5):1316-23. PubMed ID: 186555 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of cytotoxicity and antiviral activity of recombinant human interferon alfa-2a and recombinant human interferon alfa-B/D hybrid against bovine viral diarrhea virus, infectious bovine rhinotracheitis virus, and vesicular stomatitis virus in vitro. Peek SF; Bonds MD; Gangemi DG; Thomas CB; Schultz RD Am J Vet Res; 2004 Jun; 65(6):871-4. PubMed ID: 15198231 [TBL] [Abstract][Full Text] [Related]
18. Prevention of murine coxsackie B3 viral myocarditis and associated lymphoid organ atrophy with recombinant human leucocyte interferon alpha A/D. Kishimoto C; Crumpacker CS; Abelmann WH Cardiovasc Res; 1988 Oct; 22(10):732-8. PubMed ID: 2855719 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity in mice of temperature-sensitive mutants of vesicular stomatitis virus: early appearance in bronchial secretions of an interferon-like inhibitor. Beatrice ST; Wagner RR J Gen Virol; 1980 Apr; 47(2):529-33. PubMed ID: 6154132 [TBL] [Abstract][Full Text] [Related]
20. Injection of mice with antibody to interferon renders peritoneal macrophages permissive for vesicular stomatitis virus and encephalomyocarditis virus. Belardelli F; Vignaux F; Proietti E; Gresser I Proc Natl Acad Sci U S A; 1984 Jan; 81(2):602-6. PubMed ID: 6320197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]